has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.
has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.
has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.
has the objective of promoting system-oriented research of diseases by linking life sciences and informatics and establishing a systems medicine network in Germany.
e:Med has the objective of establishing systems medicine in Germany. e:Med promotes system-oriented research into diseases in order to facilitate improved prevention, more comprehensive diagnostics and individually adjusted therapy schemes in individualized medicine. The program brings together scientists with molecular-genetic, clinical, mathematical and information technology expertise, with the objective of ensuring that research results quickly benefit patients.
Electronic processing (e:Med) plays a particularly important role for unraveling scientific questions in iterative cycles of experimental studies and computer modelling approaches. The nationwide research and funding concept has been funded by the Federal Ministry of Education and Research (BMBF) since 2014.
The nine interdisciplinary research alliances of the e:Med Module I started at the end of 2019/beginning of 2020 with the support of the BMBF. In numerous sub-projects at different locations all over Germany, a common disease-related problem is being studied using systems medicine research approaches. Clinical working groups, high-throughput teams from basic biomedical research and experts in information technologies are working closely together on this.
Please note: The e:Med Kick-off Meeting 2020 in Bonn is postponed. It will take place later this year. Further information can be found on the meeting website.
Four new interdisciplinary demonstrator research networks started in the middle/end of 2019 in the e:Med Module II Demonstrators for Individualised Medicine. They are initially funded by the BMBF with 8.3 million EUR. The concrete goal of the new demonstrators is the system-oriented (further) development of innovative methods and models in order to use them directly in the individualised prevention, diagnostics and therapy of human diseases such as chronic kidney disease (NephrESA), B-cell lymphoma (SeneSys), chronic inflammatory bowel diseases (GUIDE-IBD) and addictions such as alcohol dependence (Target-OXY).
On Friday, September 27, 2019, the European Researchers‘ Night, an EU-funded initiative took place in Heidelberg / Mannheim. The e:Med Systems Medicine office was particularly well received by young visitors with their offer: their own name could be converted into the DNA code to make a very personal pearl bracelet.
Scientists from the e:Med alliance SMOOSE at the Technical University of Dortmund, in cooperation with physicians from Essen and Bochum, succeeded in producing a new AKT inhibitor, which is already showing initial efficacy against pancreatic cancer. The scientists succeeded in determining the first crystal structure of the complex of AKT1 with the new covalent alllosteric AKT inhibitor Borussertib, which provided important insights into the structural basis of the inhibition.
With this newsletter we would like to inform you about the results and activities of systems medical research in e:Med. Read about news on the development of anti-cancer agents, models for optimized drug delivery, the recurrence of glioblastomas, alcohol addiction in adolescence and the separation of relevant from irrelevant information in the brain.
Glioblastomas frequently relapse despite subsequent radiation- and chemotherapy. Are there specific mutations that enable glioblastoma cells to evade therapy? To answer this question, scientists of the e:Med alliances SYS-GLIO and SYSMED-NB jointly investigated glioblastoma tissue samples of 50 affected persons.
The BMBF funded ConISyM Summer School 2019 under direction of Prof. Dr. med. Bernd Pichler focused on image processing in systems medicine. ConISyM aimed to strengthen methodological skills of young scientists and to open up new perspectives on their own projects. The young scientists were inspired to think beyond their own research field and learned new techniques that can be applied in combination to optimize their use in answering various scientific questions.
This year's German Cancer Award in the category "Clinical Research" goes to e:Med scientist Professor Hartmut Goldschmidt. The Heidelberg doctor and scientist heads the CLIOMMICS consortium, which is working on systemic approaches to personalized multiple myeloma therapies. Next to him, Prof. Michael Baumann - scientific director of the DKFZ - and Prof. Thomas Brabletz from Erlangen receive this award in the other categories.
read more
Michael Floßdorf, Leader of the e:Med junior research group Quan-T-Cell, recieved the Special MTZ Award of the DKFZ 2017 for his outstanding research. The scientist is investiating the immunological memory development and is using nmathematical models for this approach. After his Post-Doc at the DFKZ he now started his own research group in munich.
read more
